QUOTE AND NEWS
Benzinga  Jun 22  Comment 
The Medicines Company (NASDAQ: MDCO) today announced the approval of KENGREAL(TM) (cangrelor) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural...
FierceBiotech  Jun 22  Comment 
A year after enduring a stinging FDA rejection, the Medicines Company convinced regulators to change their minds on the blood-thinning cangrelor, winning approval to treat a smaller group of patients after years of development.
FierceBiotech  May 1  Comment 
The Medicines Company won FDA approval for a pair of new acute care treatments, moving on from a series of setbacks with hopes of bagging a third nod next month.
newratings.com  May 1  Comment 
LONDON (dpa-AFX) - Exelixis Inc. (EXEL) now expects top-line results from its phase 3 pivotal trial of its drug candidate Cabozantinib in metastatic renal cell carcinoma to be available at the end of the second quarter or early in the third...
Benzinga  Apr 16  Comment 
The Medicines Company (NASDAQ: MDCO)'s blood-clot prevention drug will serve as a last-line treatment with limited sales, an analyst said Thursday. A Food and Drug Administration advisory panel on Wednesday recommended the company's cangrelor as...
Forbes  Apr 16  Comment 
On Wednesday the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-2-1 to recommend approval of cangrelor during PCI to reduce the risk of periprocedural thrombotic events such as MI, stent thrombosis, and ischemia driven...
Benzinga  Apr 15  Comment 
The Medicines Company (NASDAQ: MDCO) announced today that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted 9 - 2 with one abstention to recommend approval of the investigational...




RELATED WIKI ARTICLES
 

Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki